Third Harmonic Bio (Third Harmonic Bio) Debt-to-Equity : 0.02 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Third Harmonic Bio Debt-to-Equity?

Third Harmonic Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.75 Mil. Third Harmonic Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.21 Mil. Third Harmonic Bio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $269.09 Mil. Third Harmonic Bio's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Third Harmonic Bio's Debt-to-Equity or its related term are showing as below:

THRD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.02 Max: 0.02
Current: 0.02

During the past 4 years, the highest Debt-to-Equity Ratio of Third Harmonic Bio was 0.02. The lowest was 0.02. And the median was 0.02.

THRD's Debt-to-Equity is ranked better than
87.93% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs THRD: 0.02

Third Harmonic Bio Debt-to-Equity Historical Data

The historical data trend for Third Harmonic Bio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Third Harmonic Bio Debt-to-Equity Chart

Third Harmonic Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.02

Third Harmonic Bio Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial							0.02	0.02	0.02	0.02	0.02

Competitive Comparison of Third Harmonic Bio's Debt-to-Equity

For the Biotechnology subindustry, Third Harmonic Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Third Harmonic Bio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Third Harmonic Bio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Third Harmonic Bio's Debt-to-Equity falls into.

Third Harmonic Bio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Third Harmonic Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.745	+	3.208)	/	269.085
	=	0.01

Third Harmonic Bio's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.745	+	3.208)	/	269.085
	=	0.01

Third Harmonic Bio (NAS:THRD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Third Harmonic Bio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Third Harmonic Bio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Third Harmonic Bio (Third Harmonic Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Third Harmonic Bio Inc (NAS:THRD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1700 Montgomery Street, Suite 210, San Francisco, CA, USA, 94111

Website

https://www.thirdharmonicbio.com

Third Harmonic Bio Inc is a clinical-stage company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases.. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.

Executives

Julie Person	officer: Chief Administrative Officer	C/O THIRD HARMONIC BIO, INC., 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Edward R. Conner	officer: Chief Medical Officer	501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita	director, 10 percent owner	C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139